Carregant...
The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation
The development of biosimilars is growing rapidly, especially in Europe. They are a cost-effective alternative to original biological medicines and can help improve patient access to these therapies. The European Medicines Agency (EMA) has been the first to issue scientific guidelines related to reg...
Guardat en:
| Publicat a: | Ther Adv Drug Saf |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166315/ https://ncbi.nlm.nih.gov/pubmed/30283628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098618790442 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|